Related Experiment Video

Updated: Dec 29, 2025

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.1K

Estimating the Productivity Burden of Pediatric Pneumococcal Disease in Thailand

Thanpisit Ounsirithupsakul1, Piyameth Dilokthornsakul2, Khachen Kongpakwattana3,4

  • 1Faculty of Pharmaceutical Sciences, Department of Social and Administrative Pharmacy, Chulalongkorn University, Bangkok, Thailand.

Applied Health Economics and Health Policy
|February 4, 2020
PubMed

Insights

Pneumococcal diseases cause significant productivity loss in Thailand

Area of Science:

  • Health Economics
  • Epidemiology
  • Pediatric Health

Background:

  • Pneumococcal diseases caused an estimated 1.6 million deaths globally in 2008, disproportionately affecting children under 5.
  • The impact extends beyond mortality, causing significant productivity losses for individuals and caregivers.

Purpose of the Study:

  • To quantify the lifetime economic burden of pneumococcal diseases in Thailand's pediatric population.
  • To assess the impact using productivity-adjusted life years (PALYs).

Main Methods:

  • A decision analytic model simulated the disease burden in Thai children (0-5 years) over their lifetime.
  • Calculations included years of life lost and PALYs, with a 3% discount rate.
  • Scenario analyses evaluated the impact of pneumococcal conjugated vaccine 13 (PCV13) prevention.

Main Results:

  • The study estimated a loss of 453,401 years of life and 457,598 PALYs due to pneumococcal diseases, translating to US$5586 million.
  • PCV13 vaccination at birth could prevent 82,609 years of life and 93,759 PALYs, yielding US$1144 million in economic benefits.
  • Pneumonia incidence, vaccine efficacy, and duration of protection were key factors influencing economic outcomes.

Conclusions:

  • Pneumococcal diseases impose a substantial disease and financial burden on Thailand.
  • Vaccination, particularly with PCV13, offers a significant opportunity to mitigate these preventable losses.
Abstract

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.5K
Using the Overlay Assay to Qualitatively Measure Bacterial Production of and Sensitivity to Pneumococcal Bacteriocins06:05

Using the Overlay Assay to Qualitatively Measure Bacterial Production of and Sensitivity to Pneumococcal Bacteriocins

Published on: September 30, 2014

14.0K

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.3K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
720
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
690
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
491
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
160
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
205